GSK: participates in manufacture of Novavax's covid vaccine

(CercleFinance.com) - GSK has announced that it has reached an agreement in principle with Novavax to produce up to 60 million doses of Novavax's Covid vaccine candidate for use in the UK.


GSK will provide manufacturing capacity at its Barnard Castle facility in the North East of England from May 2021, with a rapid technology transfer between both companies, beginning immediately. The parties will negotiate a final agreement to include additional terms and conditions.

The British government secured the 60 million doses as part of an advance purchase agreement with Novavax, GSK says.

The company says that it can deliver these volumes without affecting the supply of our other life-saving medicines and vaccines, and without disrupting other COVID-19 collaborations that GSK is engaged in globally.

The Novavax vaccine candidate has demonstrated strong potential efficacy in Phase 3 clinical trials, including against the so-called 'British' variant. The vaccine's submission for review by UK regulatory authorities is expected in the second quarter, GSK said.


Copyright (c) 2021 CercleFinance.com. All rights reserved.